BillionToOne Raises 2026 Revenue Guidance Following Strong Third Quarter Results
BillionToOne (BLLN) reported strong third-quarter 2026 financial results, with revenue increasing 47% year-over-year to $123 million. The company achieved its fifth consecutive quarter of positive GAAP operating income and raised its full-year 2026 revenue guidance to a range of $460 million to $470 million. A significant driver for future growth is the upcoming December 15 launch of Northstar Clear, a tissue-free minimal residual disease (MRD) blood test. Clinical studies suggest this new assay can match or exceed the accuracy of traditional tumor-dependent tests while reducing processing delays and failure rates. The company maintains high operational efficiency with gross margins at 71%. Management attributes this profitability to software automation, AI-enabled operations, and rising average selling prices (ASP) across its prenatal and oncology testing platforms.

Tickers: $BLLN
Topics: earnings report oncology testing product launch revenue guidance
Read the full article at Motley Fool
Part of the story Cisco Raises AI Infrastructure Revenue Forecast Amid Strong Fiscal First Quarter Results (4 articles)